Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 11 of 14

4. Akero Therapeutics Inc (NASDAQ:AKRO)

Number of Hedge Fund Holders In Q4 2024: 41

Akero Therapeutics Inc (NASDAQ:AKRO) is a biotech company making treatments for metabolic diseases, particularly focusing on metabolic dysfunction-associated steatohepatitis (MASH).

The stock is up significantly so far in 2025 after it announced Phase 2b SYMMETRY study results showing a statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX).

Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group showed ≥1 stage improvement in fibrosis with no worsening of MASH. The company also posted its Q4 earnings results very recently.

The consensus price target of $75.86 implies 58.86% upside.

AKRO is up 71.75% year-to-date.

Page 11 of 14